Moderna Stock News

Moderna stock is rallying after a new strain of the Covid virus was announced. Dan Appleby looks at the company to see if it''s a buy for his portfolio. The post Is Moderna stock a buy? appeared first on The Motley Fool UK .

Oil prices slid and global stock benchmarks fell Tuesday after a warning from drugmaker Moderna that existing vaccines are unlikely to be effective against the new coronavirus variant pushed investors into safe havens such as Treasury bonds and the yen.

After Friday’s Omicron variant sell-off, things were looking pretty bleak for investors, but stocks rallied back on Monday. The Nasdaq Composite (COMP:GIDS) led the way, recovering its losses completely and adding a little more for good measure. However, the S&P 500 (SPX) and the Dow Jones Industrial Average ($DJI) were unable to recapture their losses. But the rebound has gone foul as equity index futures are pointing lower Tuesday morning. One warning the market gave yesterday was the fact that the rally was not broad-based. The NYSE only saw 54% of its stocks advancing, while the Nasdaq experienced 57% of its stocks declining. Many smaller stocks also failed to bounce back; the Russell 2000 (RUT) small-cap index dropped another 0.18%. According to Briefing.com, technology stocks were among the strongest, returning 2.6% on the strength of semiconductors. The PHLX Semiconductor Index (NASDAQ: SOX ) rallied 4.1% on the day thanks in part to Lam Research (NASDAQ: LRCX ), which closed the day 6% higher.

STOCK markets have taken a hit after the boss of Moderna predicted existing vaccines would struggle to deal with the new Omicron Covid variant. Read more here Daily Express :: City and Business Feed FTSE plummets as markets rocked by Moderna chiefs Covid warning

U.S. stocks opened sharply lower on Tuesday after a warning from vaccine maker Moderna''s CEO that COVID-19 shots could be less effective against Omicron variant.

Oxford University Says "No Evidence" Vaccines Won''t Protect Against Severe Disease Caused By Omicron After careful consideration, readers could be forgiven for believing the omicron variant is really just an early Christmas present for mRNA vaccine makers, who are pounding the alarm about the purported risks, likely because they see dollar signs. The South African scientists who initially discovered omicron (the latest in a string of variants first identified in South Africa) have already attached a giant caveat to their initial warning. They said early this week that while omicron might spread more easily than delta, early data suggest it isn''t as deadly, and that the sickness it causes is less intense. Vaccine-makers have long been waiting for these reports about a new killer mutation that might enable them to sell millions more vaccine doses in the US and around the world. Apparently, the drive to boost their top-line sales growth to meet Wall Street''s increasingly lofty expectations has overridden their purported obligation to "the science".

US stocks opened sharply lower today after a warning from vaccine maker Moderna on the effectiveness of COVID-19 shots against the Omicron variant hammered travel, energy and banking shares

The Omicron variant sparked travel restrictions from South Africa and seven other countries by the U.S.

Moderna CEO Stéphane Bancel said that while more data is needed on the omicron variant, all the scientists he has talked say, This is not going to be good.

"There is no world, I think, where (the effectiveness) is the same level . . . we had with Delta," Stéphane Bancel told the Financial Times on Monday.

The head of the company behind one of the coronavirus vaccines has said he believes there will be a material drop in the effectiveness of the jabs against the Omicron variant.

The president of the pharmaceutical company Moderna, Stefan Bancel, ruled out that vaccines against the Coronavirus (known also as COVID-19) would be effective against the new Omicron mutant, as was the case with the Delta strain. In an interview with the Financial Times (a UK daily newspaper specialized in business and politics), Stefan Bansel said []

HUMZA Yousaf today claimed calls for the reopening of mass vaccination centres were ignorant despite a booster backlog now nearing two million Scots. The Health Secretary told how there was adequate supply of Pfizer and Moderna vaccine third doses but there werent enough staff to put jabs in arms. Changing advice from expert []

U.S. stock futures and crude oil prices slumped on Nov. 30 amid a broader risk-off pivot in markets after Modernas CEO said that existing vaccines will be far less effective against the Omicron variant. Tradingview market data from around 5:15 a.m. New York time suggested Wall Streets main indexes were poised to drop on opening bell []

Notes/Observations Market shifts into a risk-off mood as Modera CEO foresaw materially lower efficacy of existing vaccines against the Omicron. EU inflation and growth data running better but ECB members maintain their dovish stance. Euro Zone Nov Preliminary CPI YoY reading of 4.9% was its 5th month above ECB target and record high since EUR [] The post Market Shifts Into A Risk-Off Mood As Moderna CEO Raises Doubts On Vaccine Efficacy appeared first on Action Forex .